Author:
Yang Lin,Alyasova Anna,Ye Dingwei,Ridolfi Antonia,Dezzani Luca,Motzer Robert J.
Funder
Novartis Pharmaceuticals Corporation
MSK Cancer Center Support Grant/Core Grant
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference9 articles.
1. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii49–56.
2. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology—Kidney Cancer [Version 3. 2016; cited 2016 June 1]. Available from:
http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
.
3. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256–65.
4. Motzer RJ, Alyasova A, Ye D, et al. Phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol. 2016;27(3):441–8.
5. Tan X, Liu Y, Hou J, Cao G. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Ther. 2015;8:313–21.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献